Start-Up Tolero Pharmaceuticals Licenses MannKind’s Btk Programme in US$130 M Deal
By Heather Cartwright
Pharma Deals Review: Vol 2012 Issue 5 (Table of Contents)
Published: 10 May-2012
DOI: 10.3833/pdr.v2012.i5.1740 ISSN: 1756-7874
Section: Licensing
Fulltext:
Abstract
In a deal worth approximately US$130 M, start-up Tolero Pharmaceuticals has licensed worldwide rights to develop and commercialise compounds from MannKind’s Btk (Bruton’s tyrosine kinase) programme, which are being developed for the treatment of haematological malignancies and inflammatory diseases...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS